Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GOFF $.0057 R/M with Huge MJ Products..
https://www.thctherapeutics.com
Announcing the Worlds First Sanitizing Cannabis Dryer.
Dry and Sanitize your Cannabis, Herbs, Flowers and Herbal Tea in Hours, not Days!
dHydronator™ gentle drying technology safely reduces moisture from herbs, plants, flowers and any object that safely fits in the drying chamber.
No damage is done to the integrity of organic matter, pollen or herbal potency with dHydronator™ patent pending warm airflow design.
Lab tested, scientifically proven drying and sanitizing technology. SanitiZen™ harnesses the power of the sun to remove surface germs, bacteria and mites.
$PXYN and other Pharmacy stocks could become interesting especially if the DEA goes for schedule 2 with marijuana - YIL3516
schedule 2 marijuana dea pot weed government money green rush chong smoke light plant grow op real estate play runner big California Colorado water electric 10 bagger board symbol acan turv phot mjtk srna hscc trtc mcig
- YIL3516
My MJ/MMJ Octopus arms are into $ACAN $TURV $SRNA $GRNH $EDXC $MCIG $HSCC ...what are yours into ??
--
marijuana dea pot weed government money green rush cheba chong smoke light plant grow op real estate play runner big California Colorado water electric 10 bagger board symbol
Louisiana on the road to medical marijuana
http://www.shreveporttimes.com/story/money/business/2016/06/30/road-medical-marijuana/85994696/
California Approves Recreational Marijuana Ballot MeasureIt could join Colorado, Washington, Oregon, Alaska and the District of Columbia in permitting recreational use for adults.
http://www.huffingtonpost.com/entry/california-recreational-marijuana_us_57733b88e4b0d1f85d47c3cf
-------
weed dea pot srna acan edxc mcig turv hscc grnh good
Democratic Senators Push DEA to Downgrade Marijuana Classification
A group of Democratic lawmakers is renewing pressure on the Drug Enforcement Administration to remove marijuana from its current position on a list of the most dangerous drugs, a category that includes heroin and ecstasy.
Marijuana’s classification as a “Schedule I” drug is “a main barrier” to research on its potential health benefits and conflicts with a decision by half of the states to approve medical marijuana laws, eight Democratic senators wrote this week in a letter to the DEA and the Department of Justice, its parent agency.
DEA spokesman Russ Baer said in an interview that the agency is in the “final stages” of its deliberation on the issue, and he said a decision on whether to reschedule marijuana is expected “sometime soon.”
Mr. Baer said he did not expect an answer by June 30, however, despite previous guidance from DEA officials that they hoped to make a decision in the first half of the year.
An increasing number of states now allow marijuana to be used for medical purposes, but the drug remains strictly illegal according to U.S. law. The federal government has adopted a practice of not prosecuting those who use marijuana according to their home-state laws.
The senators argued that this “dissonance” between state and federal laws has “wide-ranging implications for legitimate marijuana businesses, including access to banking services, the ability to deduct business expenses from taxes, and access for veterans.”
Signers of the letters are Sens. Elizabeth Warren of Massachusetts, Barbara Mikulski of Maryland, Barbara Boxer of California, Ron Wyden and Jeff Merkley of Oregon, Kirsten Gillibrand of New York, Edward J. Markey of Massachusetts, and Cory Booker of New Jersey.
(cont'd)
http://blogs.wsj.com/washwire/2016/06/24/democratic-senators-push-dea-to-downgrade-marijuana-classification/
— A DEA official responded at length today to a widely-circulated report that the DEA plans to effectively legalize medical cannabis this August.
In an interview with aNewDomain today, DEA staff coordinator Russ Baer wouldn’t confirm the Santa Monica Observer report that the DEA will reschedule cannabis as a prescription-only Schedule II drug on Aug. 1, 2016. But he did comment at length about the agency’s thoughts around legalizing medical cannabis and how rescheduling cannabis from its current Schedule I status would have to work.
Baer, in his comments, went well beyond the prepared statement the agency gave to the The Houston Chronicle and other media covering the story earlier today. Check out his comments and our takeaway below.
“This is a complicated plant.”
First off, the decision to reschedule cannabis isn’t a simple one because cannabis biochemistry is so complex, Baer said, and the variety of forms medical cannabis now takes are many.
“What is under-reported right now is how complex the marijuana plant is,” he added, pointing out that it has hundreds of chemical actors, or cannabinoids.”
THC (delta-9-tetrahydrocannabinol) and Cannabidiol (CBD) are two main ones, but even those are dramatically different. “Also, we are talking about synthetic THC, CBD (based treatments), oils, extracts edibles.” The challenge for researchers and government agencies is to “identify the parts of the plant that might have benefit, and separating out (the beneficial) parts from the ones that “aren’t beneficial or harmful.”
That the DEA is thinking about various cannabinoids as well as the many forms nascent treatments, like THC tablets for nausea in AIDs and cancer patients or CBD for easing seizures in epileptic children suggests the DEA may not be contemplating an all-or-nothing decision for cannabis, where it’s all prescription-only or nothing.
If the DEA is truly thinking hard about the different parts of the plant and the some 480 compounds it contains, as well as all the forms medical cannabis can take, that suggests a more comprehensive, structured approach is possible.
Consider this thoughtful editorial that ran a few days ago in The Denver Post. In it, cannabis policy attorney Tom Downey examined the myriad of ways the DEA decision could go.
The DEA, Downey said, “could partially legalize medical marijuana, and the federal government could usher in a new era with a comprehensive and multi-structural approach to pot policy” by rescheduling cannabis to a “federal prescription system,” leaving state decisions on medical and recreational use intact.
As you’ll see below, many of the DEA’s comments today stand in line with such an approach.
“We aren’t holding ourselves to any artificial timeframe.”
Since April, media reports have been reporting that the DEA will announce its decision on how or whether it is rescheduling cannabis, or medical cannabis products. is due on June 30 or July 1. That date comes from a 28-page DEA memo sent to a group of US senators in April. But that letter, the DEA’s Baer told aNewDomain, was leaked. But plans change. “We are not holding ourselves to any artificial timeline,” he added.
But the DEA “does already have the FDA’s scientific and health recommendation” a required step in rescheduling.
One of the interesting things about the leaked DEA letter, though, is that it fully outlines the multi-step process the DEA must go through whenever it is considering the rescheduling of a drug. That is what is required by The Controlled Substances Act of 1970, he said, “and the CSA is what drives us.”
The CSA “requires us to go through our own analysis, an eight factor analysis,” Baer added. Part of that is getting the FDA’s recommendation on the matter, “and that has already happened,” he said. “But we also have to take into account not just the FDA recommendations, but recommendations from lawyers, chemists, pharmacologists …”
The DEA is “an enforcement agency, we don’t make policy, we enforce the law … the Controlled Substance Act (of 1970) delineates what our concerns ought to be … and we follow it in every instance,” he said, remarking that “everyone thinks the DEA can do anything to anyone at any time. But it can’t. We have to act with the authority vested to us by congress, and it’s all described in the CSA.”
The supposition that the DEA can just summarily go in and change the legality of this or that drug is a big misconception the media seems to have right now, he said. The DEA follows the law, not the other way around.
And laws can change. “Congress could create and pass legislation that reschedules any substance .. they could pass a law to reschedule cannabis, Baer added.
This comment, we should not, seems relevant in light of news yesterday about the Medical Marijuana Research Act of 2016. The legislation was introduced by US representatives Sam Farr (D-CA) , Andy Harris (R-MD), Earl Blumenauer (D-OR) and H. Morgan Griffith (R-VA).
Brian Schatz (D-HI), Orrin Hatch (R-UT), Chris Coons (D-DE) and Thom Tillis (R-NC) are introducing similar legislation in the Senate, too.
In a statement about the Senate bill yesterday, Farr said the legislation is about “helping people …. as more states pass their own medical marijuana laws, it’s time for Congress to reexamine federal policy. This bill does just that by supporting research so policy decisions about the role of medical marijuana are based on science and facts instead of rhetoric,” he said.
Also, a sweeping bipartisan cannabis legalization bill that stalled in the Senate last year is reportedly being resurrected this year by US Sen. Lindsey Graham (R-SC). Called The Compassionate Access, Research Expansion, and Respect States Act of 2015, or the Carers Act for short, that bill called for the decriminalizing medical cannabis so it is available to patients and researchers, while leaving states free to make medical or recreational cannabis available to citizens if they wish.
That in particular would be a happy outcome not just for states like Colorado, which now collects some $135 million in recreational and medical cannabis taxes. Prescriptions aren’t taxed, after all.
“We do want to remove the roadblocks for research … “
One of the main reasons the DEA wants to reschedule cannabis, according to media reports, is so that it can make research easier.
“We do want to remove the roadblocks for research,” the DEA’s Baer told aNewDomain in this interview, pointing out that there are security issues and paperwork that make doing so with an illegal Schedule I substance more daunting.
This suggests that the DEA is seriously leaning toward to rescheduling at least some cannabinoids, like CBD, for instance, in the interest of spurring research.
“We want there to be research on marijuana and its component parts, there needs to be (more) studies about both the benefits and the adverse effects about marijuana,” he said, adding: “We want to remove the roadblocks for (cannabis research.) We want to know more about cannabis— we need rigorous scientific research — the DEA stands behind the scientific process.
“Safe medical cannabis use requires rigorous peer-reviewed studies,” Baer continued. “That’s true whether it’s for PTSD (patients) smoking cannabis or children with epileptic conditions … we support all (studies), but what we don’t support are decisions made on anecdotal evidence.”
And the latest studies do seem somewhat promising, he said, calling to mind the London pharmaceutical firm GW Pharmaceuticals. “GW Pharmaceuticals is showing great preliminary results with CBD (based drug research), but the results are preliminary.
“We are told by NIDA, also, that there are medical studies out there also preliminarily indicate CBD is beneficial,” Baer added.
“We’re not going to go chase after the mom who picks up cannabinol (CBD) in (one) state for her epileptic child and takes it to another state … .”
Further, DEA doesn’t want to have to go after such smokeable marijuana users as veterans with PTSD, he said.
“Marijuana is important, but most of our attention is elsewhere,” Baer explained. The cannabis rescheduling question may be top of mind with the nation’s media and the growing legal cannabis industry at large, but the DEA has bigger fish to fry.
“We have limited resources, remember,” Baer said. “Marijuana is important, but our efforts are mainly focused on the nation’s growing opioid crisis,” he said. “We’re focusing on fentanyl, fentanyl compounds and on preventing the deaths caused by opioid addiction.” Chasing around private citizens sneaking cannabis tinctures into their bags “just isn’t a priority right now.
--------------
$ACAN $HSCC $GRNH $EDXC $SRNA $TURV MJ sector MMJ pot weed $MCIG play FDA $PXYN
2016-libertarian-gary-johnson-explains-why-he-supports-marijuana-legalization
http://www.ibtimes.com/marijuana-legalization-2016-libertarian-gary-johnson-explains-why-he-supports-legal-2383547
California $PXYN needs to get involved in the Marijuana business.
dea pot mj mmj sector weed plays legal
one-injured-veteran-traded-opiate-painkillers-medical-marijuana
http://www.boston.com/news/local-news/2016/06/15/one-injured-veteran-traded-opiate-painkillers-medical-marijuana
mj sector pot acan mmj dea fda stocks grnh mcig pxyn
marijuana-sales-on-420-hit-record-highs-2016-06-14
http://www.marketwatch.com/story/marijuana-sales-on-420-hit-record-highs-2016-06-14
Legal Marijuana is Central to the Future U.S. Economy and New Companies are Sprouting like Weeds
http://massachusettsnewswire.com/legal-marijuana-is-central-to-the-future-u-s-economy-and-new-companies-are-sprouting-like-weeds-22882/
Medical-marijuana-is-now-legal-in-half-of-US-states
http://www.csmonitor.com/USA/Society/2016/0609/Medical-marijuana-is-now-legal-in-half-of-US-states
$ACAN AmeriCann Commences $2.5 Million Loan to Preferred Partner in Massachusetts
Accesswire 23 hours ago
Coastal Compassion has Started Construction on Its Registered Medical Dispensary in Fairhaven, MA
DENVER, CO / ACCESSWIRE / June 2, 2016 / AmeriCann, Inc. (ACAN), a company that designs, develops and leases sustainable, state-of-the-art medical cannabis cultivation properties, has begun funding a loan as part of a definitive agreement with Coastal Compassion, Inc. in Massachusetts.
Through AmeriCann's Preferred Partner Program, Coastal Compassion will be the first tenant in AmeriCann's proposed Massachusetts Medical Cannabis Center located in Freetown, MA. In addition, AmeriCann is providing consulting support during the construction of Coastal Compassion's approved dispensary in Fairhaven, Massachusetts.
JoAnne Leppanen, Executive Director of Coastal Compassion, stated, "We are excited to start construction on our dispensary and make progress towards providing high quality, affordable medical cannabis to Massachusetts patients."
Coastal Compassion is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health.
The 10,000 square foot building in Fairhaven will house Coastal Compassion's dispensary, which has been provisionally approved by the State. The Fairhaven facility has a Special Permit and Building Permit from the Town of Fairhaven and architectural approvals from the Department of Public Health. Once complete, the facility will begin servicing patients while AmeriCann completes the development of the Massachusetts Medical Cannabis Center.
The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. Coastal Compassion finalized agreements to occupy the first phase of the project that consists of an initial 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., for Coastal Compassion based on patient demand.
"AmeriCann and Coastal Compassion share a commitment to delivering patients unsurpassed medicine produced with sustainable practices," stated AmeriCann founder and CFO Ben Barton. "The commencement of this loan towards the completion of Coastal's medical dispensary in Fairhaven is simply the first step in a long-term partnership in serving patients in the Commonwealth."
The Massachusetts Medical Use of Marijuana Program, which was approved by voters in 2012 by a wide margin, continues to be one of the premier regarded markets by industry experts even with the first dispensaries having only recently opened.
A ballot initiative to allow for full marijuana legalization has received the necessary signatures and is expected to be on the November 2016 ballot for Massachusetts voters. "The state (Massachusetts) could become one of the biggest regulated cannabis markets in the country; bigger than Colorado and Washington State," according to Marijuana Business Daily.
About AmeriCann
Americann is a publicly traded company that designs, develops and leases sustainable, state-of-the-art medical cannabis cultivation properties. The Company has over 1,000,000 square feet of facilities in various stages of development. AmeriCann has preferred partners in Colorado, Massachusetts and Delaware. AmeriCann does not cultivate, process or distribute cannabis, but partners with local business to serve marijuana patients in their communities. More information about the Company is available at: www.americann.co.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise.
Contact Information:
Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co
Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878
SOURCE: AmeriCann, Inc.
pot mj sector weed play marijuana dea 10 bagger pot play best mmj
House Republican says he used medical marijuana while in office
http://www.cnn.com/2016/05/26/health/rohrabacher-medical-marijuana/index.html
Man'O Man Look out for $ACAN !!!
Demand for $SRNA products/ services to surge:
http://www.forbes.com/sites/elyrazin/2016/05/18/how-retail-lows-could-lead-to-marijuana-highs/#4f07c46d24ec
SKYF .0001 Sky440 to Manufacture and Distribute State of the Art Grow Containers
http://www.otcmarkets.com/stock/SKYF/news/Sky440-to-Manufacture-and-Distribute-State-of-the-Art-Grow-Containers?id=128345&b=y
http://www.otcmarkets.com/stock/SKYF/news/Sky440-Becomes-Current-With-OTC-Markets?id=126231&b=y
Company tweet May 5, 2016: "$skyf In the middle of a number of items that have required our full attention the past few days. Shareholder letter with updates on the way"
https://twitter.com/sky440inc
http://www.sky440.com/
$ACAN Boston Beer Co. selling Freetown land to marijuana facility developer
link
AmeriCann Board Approves Plan to Convert to First Medical Cannabis REIT
Accesswire April 29, 2016 8:00 AM
Developer Plans Real Estate Investment Trust (REIT) Status to Accelerate National Expansion
DENVER, CO / ACCESSWIRE / April 29, 2016 / AmeriCann, Inc. (ACAN), a company that designs, develops and owns advanced medical cannabis facilities, today announced that its Board of Directors has approved unanimously a plan for the company to pursue conversion to real estate investment trust (REIT) status. The Company expects to elect REIT status subject to completion of related preparatory work and the obtaining of necessary third-party consents.
The Company currently has projects in various stages of development in several states with over 1,000,000 square feet currently designed. The Company recently announced agreements with tenants for projects in Massachusetts and Delaware.
"This announcement to convert to a REIT is significant for our Company," stated Ben Barton, AmeriCann's Chairman. "As more states join the modernization towards regulated medical marijuana, there will be a corresponding need to build the infrastructure necessary to serve patients in these states. We believe that the REIT structure for us supports this objective and positions us to achieve a greater level of profitability and long-term shareholder value."
The investment community has developed an appreciation for the benefits of focused specialty REITs. AmeriCann's goal is to develop and own a significant portion of the estimated $27 billion in real estate that the cannabis industry will require nationwide.
AmeriCann does not cultivate, process or distribute cannabis. It develops and leases proprietary state-of-art facilities to licensed operators exclusively in regulated markets.
The Company's facilities will be designed utilizing AmeriCann's proprietary system known as "Cannopy." AmeriCann has drawn on its team's extensive experience in traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, cannabis cultivation and genetics, extraction processes, and infused product development.
AmeriCann's sustainable greenhouse designs are more energy efficient than traditional indoor warehouse facilities that rely exclusively on artificial lighting. This can lower utility bills by up to 75%. Also, harnessing natural sunlight is the best energy source for plants.
"The medical cannabis industry is one of the fastest growing segments in the country," stated Company President Tim Keogh. "The REIT status, with the potential for regular tax advantaged quarterly distributions, would provide an ideal structure for AmeriCann to obtain the capital necessary to fund our aggressive development plans."
Congress created REITS over 55 years ago in order to give all investors the opportunity to invest in large-scale, diversified portfolios of income-producing real estate. To qualify as a REIT a company must pay at least 90 percent of its taxable income in the form of shareholder dividends each year.
According to the National Association of Real Estate Investment Trusts, at the start of 2016, there were more than 200 REITs in the U.S. registered with the SEC that traded on one of the major stock exchanges. These REITs have a combined equity market capitalization of nearly $1 trillion. In 2014, listed U.S. REITs paid out $41 billion in dividends.
The process to convert to a REIT is subject to shareholder approval and requires third party consents. The Company has not yet identified a specific conversion date to REIT status. Additionally, REITs have certain ownership restrictions and distribution requirements that are unique to REITs.
About AmeriCann
AmeriCann designs, develops and owns advanced medical cannabis facilities to produce the best possible medical cannabis in the most efficient manner utilizing advanced, sustainable practices. The Company has over 1,000,000 square feet of facilities in various stages of development in Colorado, Massachusetts, Delaware, and Illinois. AmeriCann does not cultivate, process or distribute cannabis, but partners with local business to serve marijuana patients in their communities. More information about the Company is available at: www.americann.co.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended September 30, 2015, which the Company has filed with the SEC and which may be viewed at: http://www.sec.gov
Contact Information:
Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co
Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878
SOURCE: AmeriCann, Inc
ACAN .62 AmeriCann Secures First Tenant for its Massachusetts Medical Cannabis Center
Definitive Agreement with Medical Marijuana Licensee for up to 600,000 Square Feet of the Approved 1 Million Square Foot Facility
BOSTON, MA and DENVER, CO / ACCESSWIRE / April 14, 2016 / AmeriCann, Inc. (ACAN), a company that designs and develops and owns advanced medical cannabis facilities, today announced that it has signed a definitive agreement with Coastal Compassion, Inc. for the first phase in the Massachusetts Medical Cannabis Center (MMCC). The MMCC is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts.
The state-of-the-art sustainable greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. Coastal Compassion finalized agreements to occupy the first phase of the project that consists of an initial 130,000 square feet of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 square feet, for Coastal Compassion based on patient demand.
The MMCC facility has been designed utilizing AmeriCann's proprietary system known as "Cannopy." AmeriCann has drawn on its team's extensive experience in traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, cannabis cultivation and genetics, extraction techniques, and infused product development.
JoAnne Leppanen, Executive Director of Coastal Compassion, stated, "We are honored to join AmeriCann's Preferred Partner Program and become the initial tenant of the Massachusetts Medical Cannabis Center. As a non-profit committed to providing high quality, affordable medical cannabis to Massachusetts patients we take great pride in the fact that the MMCC will allow us to produce medicine using less energy and have a reduced environmental impact."
AmeriCann's sustainable greenhouse designs are more energy efficient than traditional indoor warehouse facilities that rely exclusively on artificial lighting. This can lower utility bills by up to 75%. Also, harnessing natural sunlight is the best energy source for plants.
The MMCC is the only approved medical cannabis greenhouse facility in the Commonwealth.
Coastal Compassion is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health.
In addition to building a state-of-the-art cultivation facility at the MMCC, AmeriCann will also provide Coastal Compassion with support to complete its approved dispensary in Fairhaven, Massachusetts.
"Coastal Compassion is the ideal first tenant for the MMCC," stated Ben Barton, Founder and Chairman of AmeriCann. "We share a commitment to serving patients and understand that advanced greenhouse technology is crucial to producing the most consistent and sustainable medicine."
The Massachusetts Medical Use of Marijuana Program, which was approved by voters in 2012 by a wide margin, continues to be one of the premier regarded markets by industry experts even with the first dispensaries having only recently opened.
A ballot initiative to allow for full marijuana legalization has received the necessary signatures and is expected to be on the November 2016 ballot for Massachusetts voters. "The state (Massachusetts) could become one of the biggest regulated cannabis markets in the country; bigger than Colorado and Washington State," according to Marijuana Business Daily.
About AmeriCann
AmeriCann, Inc. designs, develops and owns advanced medical cannabis facilities to produce the best possible medical cannabis in most efficient manner utilizing advanced, sustainable practices. The Company has over 1,000,000 square feet of facilities in various stages of development. AmeriCann does not cultivate, process or distribute cannabis, but partners with local business to serve marijuana patients in their communities. More information about the Company is available at: http://americann.co
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended September 30, 2015, which the Company has filed with the SEC and which may be viewed at: http://www.sec.gov
Contact Information:
Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co
Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878
SOURCE: AmeriCann, Inc.
http://www.marketwatch.com/investing/stock/sipc Looking GOOD! Happy Thanksgiving
GO SIPC!!
HBG
http://sippindustries.com/plasma-lights/ Advanced Plasma Lights for Indoor Horticulture Applications
LVGI now in the hemp business. Products shipping now and PR just out!!
MDCN - Totally agreed!!! BIG SUPREME COURT DECISION LEGALIZES ALL FORMS OF CANNABIS IN CANADA!!!
http://news.nationalpost.com/news/canada/canadian-politics/pot-cookies-brownies-oils-and-teas-legal-for-medical-marijuana-users-supreme-court
MDCN is going to BOOM!!!
MDCN
MDCN is over sold and easy 50 bagger.. Big news on MJ property closing news next week
CGRA MJ LOI is closed!!
@FostermRobert: WFCC/ CGRA completed final tweaking of lease/TI Agreement and sealed it the old Fashion way benefitting both parties http://t.co/nPlHHsBSyr
UNGS BIG MJ PLAYER. 0.0001 SWRF 0.0002 HUGE US FEDERAL CONTRACT WITH CAGE CODE
NBDR .0045 newest MJ play http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111494331
SNRY .0001 x .0002 17 mil vs 11 mil thin MJ lotto
NBDR .0039 now MJ/HEMP
http://www.otcmarkets.com/stock/NBDR/profile
No Borders, Inc. is a Nevada corporation with operations based in Southern California. The Company is positioned to benefit from the recent deregulation of Industrial Hemp throughout the United States and is in the business of planting, growing and harvesting Industrial Hemp, which will then be sold to processors of the fibrous plant. The Company will also be involved in vertically integrated businesses associated with Industrial Hemp, including but not limited to importing Hemp, extracting oils and cultivation of seeds. The Company leases 26 acres in Southern California, with an option to lease an additional 40 acres used for cultivating industrial hemp.
No longer in the telecommunication world, its HEMP time for $NBDR. MJ is hot and with this O/S of 198M
WEED is legal in Alaska now http://time.com/3719828/marijuana-legal-alaska/
CNAB has an 80 acre mmj cultivation farm in Colorado and a 3.27 million float
Legal Marijuana Is The Fastest-Growing Industry In The U.S.: Report
Huffington Post Article:
http://www.huffingtonpost.com/2015/01/25/marijuana-industry-fastest-growing_n_6540166.html
Quote:
Legal marijuana is the fastest-growing industry in the United States and if the trend toward legalization spreads to all 50 states, marijuana could become larger than the organic food industry..
Growth rate is substantial part of the equation in determining a fair market PPS for a given stock. It is nice to know that CANV is part of a rapidly growing industry and why we could see another radical jump in PPS in the coming the months.
*SHARE ME* Obama on marijuana legalization: ‘My suspicion is that you’re gonna see other states start looking at this’
By Niraj Chokshi January 22 at 6:39 PM ? Follow @NirajC
WDHR - Currently producing major wave along with solid jobs reports!
Exponential growth. Coverage in MAJOR national press, including Forbes magazine!!!
#WDHR
WDHR
CNAB 3.2 mil float first federally legal grow in California on Indian reservation
WDHR - Currently producing major wave along with solid jobs reports!
Exponential growth. Coverage in MAJOR national press, including Forbes magazine!!!
#WDHR
WDHR
WDHR - Currently producing major wave along with solid jobs reports!
Exponential growth. Coverage in MAJOR national press, including Forbes magazine!!!
#WDHR
WDHR
1/9/15 Week in Review: Big Ruling in Montana, MMJ Suggestions in Seattle & Patient Plunge in Michigan
By John Schroyer
A Montana judge rules against the state’s medical marijuana crackdown, Seattle’s city attorney suggests some radical changes to cannabis regulations, and the number of MMJ patients in Michigan tumbles.
Here’s a closer look at several notable developments in the cannabis industry over the past week:
New Lease on Life
Medical marijuana dispensaries in Montana have labored for years under the threat of prosecution, in particular due to a bill passed by the state in 2011 intended to drive most the industry out of business.
But a judge recently tossed several key portions of that law, possibly giving new life to dispensaries and related businesses that stuck it out.
The judge struck down restrictions against selling medical marijuana for profit and rules that prohibit advertising MMJ businesses. He also nixed controversial rules that impacted caregivers and patients.
FundingEBookV4 Week in Review: Big Ruling in Montana, MMJ Suggestions in Seattle & Patient Plunge in MichiganMMJ advocates praised the ruling – yet also hedged their bets.
Chris Lindsey, a legislative analyst for the Marijuana Policy Project, called it a clear victory for patients but said it might not be enough to stabilize the business climate.
Lindsey – a former caregiver and MMJ businessman in Montana – said the industry really needs the state to implement a regulatory structure to help guide and protect businesses and caregivers.
But there’s a lack of political will in the state Legislature to move forward on that front, Lindsey said.
“I think what’s going to happen in Montana is the Legislature is going to turn to law enforcement and say, ‘What do you think we need to do?'” Lindsey said. “Really, the last thing that anybody wants to do in Montana is figure out how to let the industry survive in a meaningful way.”
Controversial Recommendations
Seattle City Attorney Pete Holmes released a memo this week suggesting several regulatory changes that would impact the city’s cannabis business community in a big way – both positively and negatively.
Holmes proposed that the hundreds of dispensaries and MMJ cultivation sites in Seattle, which are operating in a legal gray area, be absorbed into the I-502 recreational regulatory structure. He also wants to close down cannabis companies that don’t have licenses from the state or are not paying taxes.
This would obviously have a devastating effect on existing medical marijuana businesses, which can’t obtain MMJ-specific state licenses because they simply don’t exist.
Still, Holmes came out strongly in support of a soon-to-be-introduced Seattle City Council measure that would legalize “marijuana use lounges,” where consumers could use edibles or vaporize marijuana. This would open up scores of new business opportunities.
Seattle attorney Ryan Agnew, who works closely with the cannabis industry, said the memo seems like a savvy push for the state’s General Assembly to deal with legal questions surrounding the MMJ industry.
“They (the city attorney’s office) want the Legislature to act. They don’t want this to come down to local enforcement,” Agnew said.
That, he added, is probably why Holmes included a suggestion in the memo that Seattle take action on its own to either force MMJ shops to conform to recreational regulations or close down.
“The big message was, ‘This is the deal we like the most…And if this isn’t passed, this is what we plan on doing,’” Agnew said. “There needs to be some regulatory authority over what (MMJ businesses are) doing, or they’re going to force local jurisdictions to come in and shut them down. And that’s money that nobody wants to spend.”
Market Shrinkage
The MMJ market in Michigan is suffering from a lack of statewide regulations and occasional raids on dispensaries brazen enough to continue operating despite a murky legal situation.
Now, the industry is facing declining patient numbers as well, with the state’s MMJ registry shrinking by nearly 20%
In the 2013 fiscal year, the state Department of Licensing and Regulatory Affairs approved 118,368 MMJ applications out of more than 133,000 received. But in the latest fiscal year, which ended on Sept. 30, that plummeted to 96,408 patients approved, according to a department spokeswoman.
That’s a decrease of 21,960 potential customers for dispensaries.
The drop could also have been affected by new patient rules that are slated to go into effect Jan. 15. While registration costs will dip for 88% of patients for a two-year registration, the new rules also eliminate a reduced rate for about 11,000 low-income patients registered with the program.
But it might not have a huge impact on the existing industry, as the messy legal situation surrounding dispensaries has limited the number of centers that have opened. So there’s still a lot of demand and not enough dispensaries to meet it.
In fact, the industry in some areas is thriving. A reported 180 MMJ dispensaries are currently operating in Detroit alone. That’s a huge increase from just a year ago, when there were an estimated 75-100 dispensaries scattered throughout the entire state.
John Schroyer can be reached at johns@mjbizmedia.com
THCZ - NEWS!!! Investors meetings all week! New website and product launch any time this month! So much more happening.
Loading zone is here and now. The ENTIRE MJ sector is heating up! People trying to get in cheap.
THCZ $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
THCZ - Investors meetings all week! New website and product launch any time this month! So much more happening.
Loading zone is here and now. The ENTIRE MJ sector is heating up!
THCZ $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
266
|
Created
|
02/28/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |